These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26782312)

  • 1. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
    Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
    Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
    Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
    Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
    Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab.
    Fagius J; Feresiadou A; Larsson EM; Burman J
    Mult Scler Relat Disord; 2017 Feb; 12():82-87. PubMed ID: 28283113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab.
    Meca-Lallana JE; Carreón-Guarnizo E; Hernández-Clares R; García-Molina E; Díaz-Pérez J; Leon-Hernández A; Zamarro-Parra J; Martín-Fernández JJ
    Neurodegener Dis Manag; 2017 Jun; 7(3):175-181. PubMed ID: 28592169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution inflammatory syndrome and natalizumab-Is it possible before removing the drug?
    Mulero P; Neri MJ; Rodriguez M; Arenillas JF; Téllez N
    Mult Scler Relat Disord; 2014 Sep; 3(5):659-61. PubMed ID: 26265277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.
    Rekik A; Aissi M; Rekik I; Mhiri M; Frih MA
    Brain Behav; 2022 May; 12(5):e2573. PubMed ID: 35398999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Toorop AA; Noteboom S; Steenwijk MD; Gravendeel JW; Jasperse B; Barkhof F; Strijbis EM; Rispens T; Schoonheim MM; van Kempen ZL; Killestein J
    Mult Scler; 2024 Feb; 30(2):266-271. PubMed ID: 38235514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
    Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
    Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
    Wiebenga OT; Schoonheim MM; Hulst HE; Nagtegaal GJ; Strijbis EM; Steenwijk MD; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
    AJNR Am J Neuroradiol; 2016 Jun; 37(6):1030-7. PubMed ID: 26965463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness and safety of natalizumab in a Portuguese population.
    Correia I; Batista S; Galego O; Marques IB; Jesus-Ribeiro J; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
    Int Immunopharmacol; 2017 May; 46():105-111. PubMed ID: 28282574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.